Allogeneic bone marrow transplantation appears to ameliorate IgA nephropathy in a patient with x-linked thrombocytopenia

Journal of Clinical Immunology

Volumn 34, Issue 1, 2014, Pages 53-57

  Hoshino, Akihiro ^a   Shimizu, Masaki ^b   Matsukura, Hiroyoshi ^c   Sakaki Nakatsubo, Hisano ^a   Nomura, Keiko ^a   Miyawaki, Toshio ^a   Kanegane, Hirokazu ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c Saiseikai Toyama Hospital   (Japan)

Author keywords

Aberrant IgA; bone marrow transplantation; IgA nephropathy; Wiskott Aldrich syndrome; X linked thrombocytopenia

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMMUNOGLOBULIN A; METHOTREXATE; PREDNISOLONE; RITUXIMAB; TACROLIMUS;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CASE REPORT; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; ELECTRON MICROSCOPY; ENGRAFTMENT SYNDROME; GLOMERULONEPHRITIS; GRAFT VERSUS HOST REACTION; HEMATURIA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY BIOPSY; LOW DRUG DOSE; LYMPHOPROLIFERATIVE DISEASE; MALE; PRIORITY JOURNAL; PROTEINURIA; THROMBOCYTOPENIA; UPPER RESPIRATORY TRACT INFECTION; WHOLE BODY RADIATION; X CHROMOSOME LINKED DISORDER; X LINKED THROMBOCYTOPENIA; YOUNG ADULT;

BIOPSY; BONE MARROW TRANSPLANTATION; GENETIC DISEASES, X-LINKED; GLOMERULONEPHRITIS, IGA; HUMANS; IMMUNOGLOBULIN A; KIDNEY; MALE; THROMBOCYTOPENIA; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84896737346     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-013-9964-4     Document Type: Article

References (26)

1. Ochs HD, Thrasher AJ. The Wiskott-Aldrich syndrome. J Allergy Clin Immunol. 2006;117:725-38.
2. Villa A, Notarangelo L, Macchi P, Mantuano E, Cavagni G, Brugnoni D, et al. X-linked thrombocytopenia and Wiskott-Aldrich syndrome are allelic diseases with mutations in the WASP gene. Nat Genet. 1995;9:414-7.
3. Imai K, Morio T, Zhu Y, Jin Y, Itoh S, Kajiwara M, et al. Clinicalcourse of patients with WASP gene mutations. Blood. 2004;103:456-64.
4. Albert MH, Bittner TC, Nonoyama S, Notarangelo LD, Burns S, Imai K, et al. X-linked thrombocytopenia (XLT) due to WAS mutations: clinical characteristics, long-term outcome, and treatment options. Blood. 2010;115:3231-8.
5. Dupuis-Girod S, Medioni J, Haddad E, Quartier P, Cavazzana-Calvo M, Le Deist F, et al. Autoimmunity in Wiskott-Aldrich syndrome: risk factors, clinical features, and outcome in a single-center cohort of 55 patients. Pediatrics. 2003;111:e622-7.
6. Boyd JK, Cheung CK, Molyneux K, Feehally J, Barratt J. An update on the pathogenesis and treatment of IgA nephropathy. Kidney Int. 2012;81:833-43.
7. Kawasaki Y. Mechanism of onset and exacerbation of chronic glomerulonephritis and its treatment. Pediatr Int. 2011;53:795-806.
8. Moldoveanu Z, Wyatt RJ, Lee JY, Tomana M, Julian BA, Mestecky J, et al. Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. Kidney Int. 2007;71:1148-54.
9. Shimizu M, Nikolov NP, Ueno K, Ohta K, Siegel RM, Yachie A, et al. Development of IgA nephropathy-like glomerulonephritis associated with Wiskott-Aldrich syndrome protein deficiency. Clin Immunol. 2012;142:160-6.
10. Humblet-Baron S, Sather B, Anover S, Becker-Herman S, Kasprowicz DJ, Khim S, et al. Wiskott-Aldrich syndrome protein is required for regulatory T cell homeostasis. J Clin Invest. 2007;117:407-18.
11. + regulatory T cells. J Exp Med. 2007;204:381-91.
12. + T cells from Wiskott-Aldrich syndrome patients. J Immunol. 2006;177:7451-61.
13. Matsukura H, Kanegane H, Miya K, Ohtsubo K, Higuchi A, Tanizawa T, et al. IgA nephropathy associated with X-linked thrombocytopenia. Am J Kidney Dis. 2004;43:e7-12.
14. Shimizu M, Kanegane H, Wada T, Motoyoshi Y, Morio T, Candotti F, et al. Aberrant glycosylation of IgA in Wiskott-Aldrich syndrome and X-linked thrombocytopenia. J Allergy Clin Immunol. 2013;131:587-90.
15. Sakai O. IgA nephropathy: current concepts and future trends. Nephrology 1997;3: 2-3.
16. Imasawa T, Nagasawa R, Utsunomiya Y, Kawamura T, Zhong Y, Makita N, et al. Bone marrow transplantation attenuates murine IgA nephropathy: role of a stem cell disorder. Kidney Int. 1999;56:1809-17.
17. Suzuki H, Suzuki Y, Aizawa M, Yamanaka T, Kihara M, Pang H, et al. Th1 polarization in murine IgA nephropathy directed by bone marrow-derived cells. Kidney Int. 2007;72:319-27.
18. Inoue T, Sugiyama H, Kikumoto Y, Fukuoka N, Maeshima Y, Hattori H, et al. Downregulation of the beta1, 3- galactosyl transferasegene in tonsillar B lymphocytes and aberrant lectin bindings to tonsillar IgA as a pathogenesis of IgA nephropathy. Contrib Nephrol. 2007;157:120-4.
19. Yamada K, Kobayashi N, Ikeda T, Suzuki Y, Tsuge T, Horikoshi S, et al. Down-regulation of core 1 beta1, 3-galactosyl transferase and Cosmc by Th2 cytokine alters O-glycosylation of IgA1. Nephrol Dial Transplant. 2010;25:3890-7.
20. Suzuki H, Moldoveanu Z, Hall S, Brown R, Vu HL, Novak L, et al. IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1. J Clin Invest. 2008;118:629-39.
21. Suzuki H, Suzuki Y, Narita I, Aizawa M, Kihara M, Yamanaka T, et al. Toll-like receptor 9 affects severity of IgA nephropathy. J Am Soc Nephrol. 2008;19:2384-95.
22. Park HJ, Hahn WH, Suh JS, Kim MJ, Kang SW, Lee JS, et al. Association between toll-like receptor 10 (TLR10) gene polymorphisms and childhood IgA nephropathy. Eur J Pediatr. 2011;170:503-9.
23. Kobayashi I, Nogaki F, Kusano H, Ono T, Miyawaki S, Yoshida H, et al. Interleukin-12 alters the physicochemical characteristics of serum and glomerular IgA and modifies glycosylation in a ddY mouse strain having high IgA levels. Nephrol Dial Transplant. 2002;17:2108-16.
24. Cuevas X, Lloveras J, Mir M, Aubia J, Masramon J. Disappearance of mesangial IgA deposits from the kidneys of two donors after transplantation. Transplant Proc. 1987;19:2208-9.
25. Koselj M, Rott T, Kandus A, Vizjak A, Malovrh M. Donor-transmitted IgA nephropathy: long-term follow-up of kidney donors and recipients. Transplant Proc. 1997;29:3406-7.
26. Ozsahin H, Cavazzana-Calvo M, Notarangelo LD, Schulz A, Thrasher AJ, Mazzolari E, et al. Long-term outcome following hematopoietic stem-cell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation. Blood. 2008;111:439-45.